Antibiotic-Impregnated Catheters: The 28-Day Release Explained

An antibiotic-impregnated catheter carries the agent within the catheter material itself. DESU’s orange antibiotic-impregnated catheters are designed to release that agent in a controlled way over 28 days, covering the period when an external drain is most commonly in place. For a value-analysis committee, the point is a defined, sustained release, not a promise of zero infections.

Value-analysis committees hear many infection claims. The ones that win their trust are precise about what a product does and honest about what it cannot do. This article gives distributors and clinical champions a clear way to explain the 28-day controlled release, and the questions to expect.

What does “impregnated” actually mean?

In an impregnated catheter, the antimicrobial agent is incorporated into the silicone, so it is present throughout the wall rather than sitting on the outside. The agent then moves out of the material gradually. That is why DESU uses the word impregnated: it describes where the agent is and how it becomes available.

The distinction matters to a committee because it explains the release profile. A substance placed only on a surface can be lost quickly. An agent distributed within the material can be released over a longer, more predictable period.

Why does a 28-day release window matter?

Catheter-associated ventriculitis is one of the most serious complications of external ventricular drainage, and the risk is linked to how long the drain stays in, how often the system is accessed and how carefully it is handled. Many drains remain for days to a few weeks. A release designed to continue over 28 days is intended to cover that window rather than only the first days after placement.

The honest framing is “designed to help reduce the risk of catheter colonization over the period the drain is typically in place.” Avoid any language that suggests the catheter can stop infection on its own.

How does the release window line up with drain duration?

A committee will reasonably ask whether 28 days is relevant to its own patients. The best answer comes from the hospital’s data, not from the manufacturer. Ask the neuro-ICU or quality team for a simple distribution of EVD duration over the past year: how many drains were removed within a week, within two weeks and later. Most committees already have this from their infection surveillance work.

Then place the release window against that distribution. If most drains are removed or converted to a shunt well within 28 days, the release period covers the full time the catheter is in place for most patients. If the unit regularly manages very long drainage periods, the discussion turns to catheter exchange policy and to the other bundle elements. Either way, the committee sees the product facts set against its own practice, which is far more persuasive than a general claim.

The same logic applies to lumbar drains and to shunt catheters. A lumbar drain is often in place for a shorter period, while a shunt catheter is permanent and the early postoperative weeks are the focus. Presenting the 28-day release in the context of each use keeps the conversation accurate and specific.

Which DESU products offer the antibiotic-impregnated option?

The antibiotic-impregnated version is easy to identify by its orange color. It is available across the external drainage and catheter range, including:

• The ventricular catheter kit: radiopaque silicone, tantalum length marks from 5 to 15 cm, 24 drainage holes in four rows, standard or antibiotic-impregnated with 28-day controlled release.
• The EVD-010 Series: external ventricular drainage system offered with a standard or an antibiotic-impregnated 31 cm ventricular catheter.
• The lumbar drainage catheter kit: 80 cm silicone catheter for external lumbar drainage, in standard and antibiotic-impregnated versions.
• Shunt catheter kits, which matters when an EVD patient later needs permanent diversion.

How should the committee packet present it?

A good packet separates facts from interpretation. One way to structure the antibiotic-impregnated section:

What questions will a committee ask?

“Does it reduce infections?”

Answer carefully. Published literature and consensus statements discuss antimicrobial catheters as one of several measures in EVD infection prevention, alongside insertion technique, sterile handling and minimizing system access. The catheter is designed to help reduce the risk of colonization. Clinical outcomes depend on the whole bundle and on local practice.

“Which patients should get it?”

That is the hospital’s decision. Some institutions use antibiotic-impregnated catheters for all external drains; others reserve them for patients with expected longer drainage or other risk factors. A rep can support the protocol discussion but should not set it.

“Does the agent affect our microbiology?”

Infection prevention and pharmacy teams may ask about the agent and about interpretation of CSF cultures. Route these questions to the manufacturer for documented answers. DESU does not discuss specific agents in marketing material; technical documentation is provided to institutions directly.

“Why not use it for every patient?”

Cost, stewardship policy and clinical preference all play a part. Offering both versions lets the hospital match the catheter to its protocol rather than adapting the protocol to a single product.

How should reps talk about it, and what should they avoid?

Language is where many presentations lose a committee. A simple rule set helps:

• Say “antibiotic-impregnated,” not any other description of the catheter.
• Say “designed to” and “intended to help reduce the risk,” and avoid absolute words that promise an outcome.
• Do not quote infection rates unless they come from a published source the committee can read.
• Present the catheter as one element of an infection prevention bundle.
• Refer clinical and microbiological questions to the manufacturer for written answers.

What does a workable selection protocol look like?

Committees often adopt the catheter more readily when the clinical team presents a simple, written selection rule alongside it. The rule belongs to the hospital, but a distributor can help by showing the format other teams use. A typical structure covers:

• Which clinical situations call for the antibiotic-impregnated version, as defined by the neurosurgery and infection prevention leads.
• Who makes the selection at the time of placement and where it is documented.
• How the orange catheter is stocked and labeled in each location where drains are placed.
• How the protocol will be reviewed after a set period, using the hospital’s own surveillance data.

A protocol of this kind turns the purchasing decision into a clinical policy with an owner and a review date. That reassures a committee that the product will be used as intended rather than chosen ad hoc at the bedside.

Stocking and cost

If the hospital adopts a selective protocol, both catheter versions need to be stocked, with par levels reflecting the expected split. The color difference helps staff pick the right item. For total cost discussions, keep the focus on what the hospital controls: number of items, waste from expiry, and how one manufacturer covering both versions simplifies purchasing.

Talk to a DESU product specialist

If you are preparing a value-analysis packet that includes antibiotic-impregnated catheters, DESU’s product specialists can provide documentation, help you structure the presentation and answer technical questions for your market. Email sales@desu.tr or use the contact page.